Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues.
The ras oncogene p21 antigen (p21) has been identified in several epithelial malignancies, including breast, colon, bladder, and prostate. The pattern and intensity of immunoreactivity between normal and neoplastic tissues has been distinctly different. The authors examined thyroid lesions from 73 different cases by immunohistochemistry for the expression of p21 with a monoclonal antibody (RAP-5). Normal thyroid tissues (4) showed the least immunoreactivity, while papillary carcinomas (8), Hurthle cell carcinomas (10), and follicular carcinomas as (3) showed slightly more intense staining than Hurthle cell adenomas (12) or follicular adenomas (9). Anaplastic carcinomas (4) showed much less intense staining than most other carcinomas, while medullary thyroid carcinomas (5) showed only slight immunoreactivity. Inflammatory thyroid lesions associated with goiters, including Hashimoto's thyroiditis (6) and Graves' disease (8), showed moderate to intense expression of p21 as did multinodular goiters (4). Semiquantitative analysis of staining intensity by serial dilution of the primary antibody showed significant differences in staining between normal thyroid and some carcinomas (P less than 0.05), but not between carcinomas and adenomas. These results show that while antibody RAP-5 detects an antigen that is only weakly expressed in normal thyroids, this antigen is more strongly expressed in benign and malignant thyroid tumors, as well as in inflammatory and nonneoplastic proliferative thyroid lesions. It is thus not helpful in identifying differences between neoplastic and non-neoplastic thyroid lesions.
D000236:Adenoma / Q000378:metabolism / Q000473:pathology; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000032:analysis; D002277:Carcinoma / Q000378:metabolism / Q000473:pathology; D002455:Cell Division; D004848:Epithelium / Q000378:metabolism; D019204:GTP-Binding Proteins / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D007124:Immunoenzyme Techniques; D009842:Oligopeptides / Q000276:immunology; D011518:Proto-Oncogene Proteins / Q000276:immunology / Q000378:metabolism*; D013959:Thyroid Diseases / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D013961:Thyroid Gland / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D013964:Thyroid Neoplasms / Q000276:immunology / Q000378:metabolism* / Q000473:pathology
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D009842:Oligopeptides; D011518:Proto-Oncogene Proteins; D019204:GTP-Binding Proteins